Endocrine Abstracts

It is well known that cannabinoid type 1 receptor (CB1) antagonist drugs may reduce body weight and improve metabolic profiles in obese animals and humans by a double mechanism: at first, targeting mesolimbic and hypothalamic nuclei and, thereafter, peripheral organs involved in energy storage and expenditure. However, it is still unknown which of these sites of action may have a predominant role in the endocannabinoid effect on energy balance regulation. To solve this questio...

The pharmacological blockade of cannabinoid receptor type 1 (CB1) has been shown to counteract diet induced obesity (DIO). An unsolved question is whether the effects of CB1 blockade on energy balance are due to peripheral or central mechanisms. This is an important clinical issue since the CB1 antagonist drugs have recently been withdrawn from the market due to their psychiatric side effects, and novel drugs selectively acting at peripheral le...

Aims: Recently, the endocannabinoid system emerged as a pivotal regulator of food intake, ingestive behavior and energy metabolism, acting through CB1 and its endogenous ligands, the endocannabinoids. CB1 antagonists may reduce body weight and improve metabolic profiles in animals and humans by a double mechanism: at first, they target mesolimbic and hypothalamic nuclei and, thereafter, peripheral organs involved in energy storage and expenditure. Nevertheless, it is still unk...